Weekly Recap: Axelios challenges Illumina and Guggenheim lifts ILMN target to $200

Illumina (NASDAQ:ILMN) faces fresh competitive pressure as Roche launches the $750,000 Axelios NGS system aimed at its NovaSeq X franchise, even as Guggenheim raised Illumina’s price target to $200, signaling confidence in its valuation amid the market challenge.

Previous Week Recap

• Roche Unveils Axelios NGS System: Illumina (ILMN) faces new competition as Roche unveils the $750,000 Axelios NGS system, targeting Illumina’s dominant NovaSeq X market share and adding pressure on Illumina’s sequencing business.
• Guggenheim Raises Illumina Target: Guggenheim raised its price target for Illumina (ILMN) to $200.00 per share from $180.00, reflecting an upward revision in the firm’s valuation guidance for the company.

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.